Date: 17th April, 2017

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd
'Exchange Plaza',
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 051

Dear Sir/Madam,

Sub: Successful US FDA Inspection at Alembic Pharmaceuticals Bioequivalence Facility at Baroda

This is to inform the exchange that the Company's Bioequivalence facility located at Baroda was inspected by US Food & Drug Administration (FDA) between 6th March, 2017 & 10th March, 2017, between 13th March, 2017 & 17th March, 2017 and between 10th April, 2017 to 12th April, 2017 for

a) Bioequivalence Clinical
b) Bioequivalence Bioanalytical
c) Pharmacovigilance

There were no 483s issued by US FDA at the end of the inspection.

Please find enclosed herewith our press release.

We request you to kindly take the same on record.

Thanking you,

Yours Faithfully,
For Alembic Pharmaceuticals Limited

R. K. Baheti
Director - Finance & CFO

Encl.: A/a.

PRESS RELEASE

17th April 2017, Vadodara, India

Successful US FDA Inspection at Alembic Pharmaceuticals Bioequivalence Facility at Baroda

Alembic Pharmaceuticals Limited today announced that the US Food & Drug Administration (US FDA) inspected its Bioequivalence facility at Baroda (Gujarat, India) between 6th & 10th March, 2017, between 13th & 17th March, 2017 and between 10th & 12th April, 2017 for

a) Bioequivalence Clinical
b) Bioequivalence Bioanalytical
c) Pharmacovigilance

All have been successfully cleared without any 483 observations.

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembic-india.com; (Reuters: ALEM.NS) (Bloomberg: ALPM) (NSE: APLLTD) (BSE: 533573)

For further information contact:

Ajay Kumar Desai Phone: +91 22 – 306 11681 Email: ajay.desai@alembic.co.in	Mitanshu Shah Phone: +91 265 – 3007630 Email: mitanshu.shah@alembic.co.in

Disclaimer:

This press release contain statements that may constitute "forward looking statements" including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward looking statements to reflect future events or circumstances and will not be held liable for any use of this information.

ALEMBIC PHARMACEUTICALS LIMITED VADODARA